Allogene Therapeutics Inc (ALLO)

$1.33 +0.04 (3.10%)
Market Cap 295.10M
Revenue (ttm) 20,000.00
Net Income (ttm) -257.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,287,950.01%
Debt to Equity Ratio 0.00
Volume 2,435,900
Avg Vol 4,117,390
Day's Range N/A - N/A
Shares Out 221.88M
Stochastic %K 95%
Beta 0.43
Analysts Strong Sell
Price Target $7.56

Company Profile

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineer...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 457 2700
Address:
210 East Grand Avenue, South San Francisco, United States
Vikingsstrade
Vikingsstrade Oct. 4 at 5:59 PM
Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $KRUS $VERO $GTI $ALLO
0 · Reply
tradersunion353
tradersunion353 Oct. 4 at 3:37 AM
$ALLO Scam
0 · Reply
longrigger52
longrigger52 Oct. 3 at 8:16 PM
$ALLO 3 month closing high....this will revisit 1.70 next week....FU tradersunion
0 · Reply
tradersunion353
tradersunion353 Oct. 3 at 4:52 PM
$ALLO Scam dropped $47 since IPO which is 98.5% share value Scam is now struggling to be up by 2-3 cents Meanwhile pumpers here and on yah oo boards are getting high for this 2-3 cents bump 😂😂😂
0 · Reply
tr1llA
tr1llA Oct. 3 at 1:54 PM
$ALLO almost back at breakeven of 1.35
0 · Reply
rlkloehn
rlkloehn Oct. 3 at 3:59 AM
$ALLO worth a listen https://ir.allogene.com/events
0 · Reply
MOTP
MOTP Oct. 2 at 9:23 PM
$ALLO Interesting to understand the bearish sentiment when the Street seems to be bullish with an average PT at $7.51? I don’t one this stock. Just a curious passerby.
1 · Reply
tradersunion353
tradersunion353 Oct. 2 at 8:19 PM
$ALLO $48 to $1.29 What a earth shattering move 🤣 Pumpers here are crazy
0 · Reply
tradersunion353
tradersunion353 Oct. 1 at 7:56 PM
$ALLO This scam has lost 98.5% share value But its appetite to drop further more wont stop Next stop 50 cents Reason ? Was there any reason for scam to drop from $48 to $1 ? Just stay away from this brutal scam
0 · Reply
highnihilism
highnihilism Oct. 1 at 10:37 AM
$FOXF Fox Factory Holdings Trades: 10 | Total $: 1.8 K | 90D Avg: 11.4 K | Rel. Notional: 0.16 | Call $: 1.4 K | Put $: 411 | % Single-Leg: 89% | % Multi-Leg: 11% | % Contingent: – $ALLO Allogene Therapeutics Trades: 54 | Total $: 1.8 K | 90D Avg: 9.6 K | Rel. Notional: 0.19 | Call $: 1.4 K | Put $: 399 | % Single-Leg: 94% | % Multi-Leg: 6% | % Contingent: – $RRX Regal Rexnord Trades: 11 | Total $: 4.1 K | 90D Avg: 137.9 K | Rel. Notional: 0.03 | Call $: 1.4 K | Put $: 2.7 K | % Single-Leg: 69% | % Multi-Leg: 31% | % Contingent: – $WTBA West Bancorporation Trades: 6 | Total $: 1.7 K | 90D Avg: 6.2 K | Rel. Notional: 0.27 | Call $: 1.4 K | Put $: 270 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: –
0 · Reply
Latest News on ALLO
Allogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 Transcript

Oct 4, 2025, 12:22 AM EDT - 21 hours ago

Allogene Therapeutics, Inc. (ALLO) Presents at Citi's SMID Call Series 2025 Transcript

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

Aug 27, 2025, 8:30 AM EDT - 5 weeks ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conference

Allogene Therapeutics: Important Catalysts Guided For Early 2026

Aug 14, 2025, 3:02 PM EDT - 7 weeks ago

Allogene Therapeutics: Important Catalysts Guided For Early 2026

Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 9:13 PM EDT - 7 weeks ago

Allogene Therapeutics, Inc. (ALLO) Q2 2025 Earnings Call Transcript

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Aug 13, 2025, 4:05 PM EDT - 7 weeks ago

Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Aug 6, 2025, 8:30 AM EDT - 2 months ago

Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Aug 1, 2025, 8:30 AM EDT - 2 months ago

Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Jun 1, 2025, 10:45 AM EDT - 4 months ago

Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment

May 29, 2025, 3:37 PM EDT - 4 months ago

Allogene Therapeutics: Buying Around A Potential ASCO Lazarus Moment

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)

May 28, 2025, 9:43 AM EDT - 4 months ago

Allogene Therapeutics: Still Looking Shaky, But Looking To Turn The Corner (Rating Upgrade)

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

May 23, 2025, 8:30 AM EDT - 4 months ago

Allogene Therapeutics Announces Participation in Upcoming Investor Conferences

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

May 22, 2025, 5:17 PM EDT - 4 months ago

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript

May 13, 2025, 10:47 PM EDT - 5 months ago

Allogene Therapeutics, Inc. (ALLO) Q1 2025 Earnings Call Transcript

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

May 13, 2025, 4:05 PM EDT - 5 months ago

Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

May 6, 2025, 8:30 AM EDT - 5 months ago

Allogene Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 23, 2025, 10:12 AM EDT - 5 months ago

Allogene Therapeutics to Present Updated ALLO-316 Clinical Results in Kidney Cancer in Oral Presentation and ALPHA3 Trial-in-Progress Poster for Cema-Cel at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Apr 7, 2025, 8:30 AM EDT - 6 months ago

Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma

Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript

Mar 13, 2025, 11:56 PM EDT - 7 months ago

Allogene Therapeutics, Inc. (ALLO) Q4 2024 Earnings Call Transcript

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Mar 13, 2025, 4:02 PM EDT - 7 months ago

Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Mar 3, 2025, 8:30 AM EST - 7 months ago

Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update

Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities

Feb 26, 2025, 10:52 AM EST - 7 months ago

Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities

Allogene Therapeutics Announces Participation in March Investor Conference

Feb 26, 2025, 8:30 AM EST - 7 months ago

Allogene Therapeutics Announces Participation in March Investor Conference

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Feb 25, 2025, 4:10 PM EST - 7 months ago

Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model

Feb 24, 2025, 10:53 PM EST - 7 months ago

Allogene Therapeutics: Disrupting CAR-T With A Scalable Model

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Feb 13, 2025, 4:30 PM EST - 8 months ago

Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Jan 28, 2025, 8:30 AM EST - 8 months ago

Allogene Therapeutics Secures U.S. FDA IND Clearance for ALLO-329, Advancing its Next-Generation Allogeneic CAR T into Autoimmune Diseases

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 16, 2024, 8:30 AM EST - 10 months ago

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Dec 12, 2024, 8:30 AM EST - 10 months ago

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Allogene Therapeutics Announces Participation in December Investor Conferences

Nov 19, 2024, 8:30 AM EST - 11 months ago

Allogene Therapeutics Announces Participation in December Investor Conferences

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Nov 18, 2024, 8:30 AM EST - 11 months ago

Allogene Therapeutics Presents Preclinical Data for ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Disease at the American College of Rheumatology (ACR) Convergence

Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 8:59 PM EST - 11 months ago

Allogene Therapeutics, Inc. (ALLO) Q3 2024 Earnings Call Transcript

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Nov 7, 2024, 4:02 PM EST - 11 months ago

Allogene Therapeutics Reports Third Quarter 2024 Financial Results and Business Update

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Nov 7, 2024, 10:00 AM EST - 11 months ago

Allogene Therapeutics Announces Positive Phase 1 Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Patients with Advanced Renal Cell Carcinoma at SITC and IKCS

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Nov 5, 2024, 9:10 AM EST - 11 months ago

Allogene Therapeutics to Present New Data Demonstrating the Potential of ALLO-316 in Heavily Pretreated Adult Patients with CD70 Positive Advanced Renal Cell Carcinoma (RCC) at the International Kidney Cancer Symposium (IKCS) and Society for Immunotherapy of Cancer (SITC) Annual Meeting

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Oct 30, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Oct 2, 2024, 4:11 PM EDT - 1 year ago

Allogene Therapeutics (ALLO) Stock Drops Over 5% Amid Market Activity

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Sep 30, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

Aug 26, 2024, 11:39 PM EDT - 1 year ago

Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell Therapies

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript

Aug 10, 2024, 12:34 AM EDT - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q2 2024 Earnings Call Transcript

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Aug 7, 2024, 4:02 PM EDT - 1 year ago

Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business Update

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Jul 31, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Jul 1, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

Jun 20, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

Jun 12, 2024, 1:09 PM EDT - 1 year ago

Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

May 23, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit

Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript

May 13, 2024, 7:31 PM EDT - 1 year ago

Allogene Therapeutics, Inc. (ALLO) Q1 2024 Earnings Call Transcript

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

May 13, 2024, 4:47 PM EDT - 1 year ago

Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

May 13, 2024, 4:01 PM EDT - 1 year ago

Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

May 6, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Apr 26, 2024, 8:30 AM EDT - 1 year ago

Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell Carcinoma

Vikingsstrade
Vikingsstrade Oct. 4 at 5:59 PM
Merger news on NITO and it barely has 3 million market cap. If people find this, short sellers could get hurt alot on NITO. Small caps have been dead for a while, but NITO gives me hope that short sellers finally get what they deserve! $KRUS $VERO $GTI $ALLO
0 · Reply
tradersunion353
tradersunion353 Oct. 4 at 3:37 AM
$ALLO Scam
0 · Reply
longrigger52
longrigger52 Oct. 3 at 8:16 PM
$ALLO 3 month closing high....this will revisit 1.70 next week....FU tradersunion
0 · Reply
tradersunion353
tradersunion353 Oct. 3 at 4:52 PM
$ALLO Scam dropped $47 since IPO which is 98.5% share value Scam is now struggling to be up by 2-3 cents Meanwhile pumpers here and on yah oo boards are getting high for this 2-3 cents bump 😂😂😂
0 · Reply
tr1llA
tr1llA Oct. 3 at 1:54 PM
$ALLO almost back at breakeven of 1.35
0 · Reply
rlkloehn
rlkloehn Oct. 3 at 3:59 AM
$ALLO worth a listen https://ir.allogene.com/events
0 · Reply
MOTP
MOTP Oct. 2 at 9:23 PM
$ALLO Interesting to understand the bearish sentiment when the Street seems to be bullish with an average PT at $7.51? I don’t one this stock. Just a curious passerby.
1 · Reply
tradersunion353
tradersunion353 Oct. 2 at 8:19 PM
$ALLO $48 to $1.29 What a earth shattering move 🤣 Pumpers here are crazy
0 · Reply
tradersunion353
tradersunion353 Oct. 1 at 7:56 PM
$ALLO This scam has lost 98.5% share value But its appetite to drop further more wont stop Next stop 50 cents Reason ? Was there any reason for scam to drop from $48 to $1 ? Just stay away from this brutal scam
0 · Reply
highnihilism
highnihilism Oct. 1 at 10:37 AM
$FOXF Fox Factory Holdings Trades: 10 | Total $: 1.8 K | 90D Avg: 11.4 K | Rel. Notional: 0.16 | Call $: 1.4 K | Put $: 411 | % Single-Leg: 89% | % Multi-Leg: 11% | % Contingent: – $ALLO Allogene Therapeutics Trades: 54 | Total $: 1.8 K | 90D Avg: 9.6 K | Rel. Notional: 0.19 | Call $: 1.4 K | Put $: 399 | % Single-Leg: 94% | % Multi-Leg: 6% | % Contingent: – $RRX Regal Rexnord Trades: 11 | Total $: 4.1 K | 90D Avg: 137.9 K | Rel. Notional: 0.03 | Call $: 1.4 K | Put $: 2.7 K | % Single-Leg: 69% | % Multi-Leg: 31% | % Contingent: – $WTBA West Bancorporation Trades: 6 | Total $: 1.7 K | 90D Avg: 6.2 K | Rel. Notional: 0.27 | Call $: 1.4 K | Put $: 270 | % Single-Leg: 100% | % Multi-Leg: 0% | % Contingent: –
0 · Reply
tradersunion353
tradersunion353 Sep. 30 at 7:01 PM
$ALLO Scam alert 🚨 Lost 98.5% share value since IPO Also Huge Red flag ⛔️ Heavy insider selling even at $1 range
0 · Reply
Southshd
Southshd Sep. 30 at 6:37 PM
$ALLO FATE is having a good day on high volume today, this will follow tomorrow.
0 · Reply
Mikrus36
Mikrus36 Sep. 30 at 5:51 PM
$ALLO this stock is fu.king shity
0 · Reply
AngieConners337
AngieConners337 Sep. 30 at 5:38 PM
$ALLO With McGregor’s fanbase, BKFC gets global reach instantly. That means RMTG’s regenerative medicine will be seen and talked about on a worldwide stage.
0 · Reply
RobertMinnick227
RobertMinnick227 Sep. 29 at 5:03 PM
$ALLO is strengthening its position. FDCT highlights the importance of combining innovation and regulated growth to expand market reach.
0 · Reply
BeefandCheese
BeefandCheese Sep. 29 at 4:37 PM
$ALLO
0 · Reply
tradersunion353
tradersunion353 Sep. 27 at 3:55 PM
$ALLO Scam Alert 🚨 Look at the ugly 3, 6 months, 1 and5 years chart Lost 98.5% share value No doubt insiders were not confident about this scam and sold all their shares
0 · Reply
Taurusthebullman
Taurusthebullman Sep. 27 at 2:07 PM
$ALLO hahahahah bot has gone into overdrive 😆😆😆👇👇👇👇👇.... Probably means something good is coming...
1 · Reply
tradersunion353
tradersunion353 Sep. 26 at 3:40 PM
$ALLO Reverse split coming soon ..
1 · Reply
tradersunion353
tradersunion353 Sep. 26 at 2:39 PM
$ALLO Dropping to 50 cents and reverse split coming soon
0 · Reply
tradersunion353
tradersunion353 Sep. 26 at 12:20 AM
$ALLO Scam is heading to 50 cents
0 · Reply
tradersunion353
tradersunion353 Sep. 24 at 8:20 PM
$ALLO Look at the ugly 3, 6 months, 1 and5 years chart Lost 98.5% share value No doubt insiders were not confident about this scam and sold all their shares
0 · Reply